LRCH2

Across TCGA pan-cancer cohorts, LRCH2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated LRCH2 data layer compared with 25 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher LRCH2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated LRCH2 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

PDAC, UCEC, and LSCC are the cancer types where LRCH2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	III,IV	0.173	0.834	.038	12	view →
UCEC	OS	Median	III,IV	0.413	1.000	.026	4	view →
LSCC	OS	Tertile	II,III,IV	0.875	1.000	.045	1	view →
LUAD	OS	Median	All	0.924	0.686	.028	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

LRCH2–PDAC (DFS)

Open the PDAC breakdown →